(READ) Medicare won’t pay for controversial Alzheimer’s drug except for patients in studies

Medicare will only pay for patients to take a controversial new Alzheimer’s drug if they are enrolled in an approved study. That policy decision from the federal government is the latest blow to aducanumab, being sold by Biogen under the brand name Aduhelm. The FDA astonished many in the medical community by approving the drug […]

Share DeepPol